Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Patients With Mild to Moderate Alzheimer's Disease
NCT05383183 is registered in ClinicalTrials.gov with Daewoong Bio Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Patients With Mild to Moderate Alzheimer's Disease
- Lead sponsor
- Daewoong Bio Inc.
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 20, 2022
- Completion date
- December 9, 2025
- Enrollment
- 630 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.